Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Octreotide as primary therapy for acromegaly

C B Newman1, S Melmed, A George

  • 1Department of Medicine, New York University, New York, USA.

The Journal of Clinical Endocrinology and Metabolism
|September 24, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gender-affirming care in South Africa: A cross-sectional survey of transgender and gender-diverse people in the Eastern and Western Cape provinces, South Africa.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2026
Same author

Parenteral artesunate compliance and hospital outcomes in children under five with suspected severe malaria in Sierra Leone.

Public health action·2026
Same author

SIGNIFIED: whole-body MRI screening in Li-Fraumeni syndrome in the UK.

ESMO open·2026
Same author

Extension of the intravitreal injection interval after switching to faricimab in patients with exudative AMD: The multicenter FAR WEST study.

Journal francais d'ophtalmologie·2026
Same author

Li Fraumeni syndrome in the UK: clinical characteristics and outcomes of TP53 carriers.

ESMO open·2025
Same author

Embedding systems thinking in local authority public health practice: a case study.

Perspectives in public health·2025

Octreotide effectively treated acromegaly in both new patients and those previously treated with surgery or radiation. This finding suggests reconsidering initial surgical approaches for growth hormone-secreting pituitary adenomas.

Area of Science:

  • Endocrinology
  • Oncology
  • Pharmacology

Background:

  • Acromegaly is a disorder caused by excess growth hormone (GH).
  • Current treatment often involves surgery, but efficacy varies.
  • Octreotide is a somatostatin analog used to manage acromegaly.

Purpose of the Study:

  • To compare the efficacy of octreotide as a primary treatment versus secondary/adjunctive therapy for acromegaly.
  • To evaluate the long-term effects of octreotide on GH, IGF-I, and acromegaly symptoms.

Main Methods:

  • A multicenter study comparing octreotide in 26 primary treatment patients vs. 81 secondary treatment patients.
  • Randomized treatment phases with varying octreotide doses (100-250 mcg) administered subcutaneously every 8 hours.
  • Long-term open-label treatment with dose titration based on individual patient response.

Related Experiment Videos

Main Results:

  • Octreotide demonstrated comparable efficacy in reducing GH and IGF-I levels in both primary and secondary treatment groups.
  • Significant symptom improvement (headache, perspiration, fatigue, joint pain) was observed in both groups.
  • Tumor shrinkage occurred in some patients, but did not correlate with hormonal level reduction.

Conclusions:

  • Octreotide is an equally effective treatment option for both previously untreated acromegaly patients and those with prior surgical or radiation therapy.
  • The findings challenge the routine surgical resection of all newly diagnosed GH-secreting pituitary adenomas.
  • Octreotide offers a viable alternative or adjunctive therapy, potentially altering current treatment paradigms.